News
ESAIY
8.21
+0.74%
0.06
Weekly Report: what happened at ESAIY last week (0209-0213)?
Weekly Report · 5d ago
Eisai GAAP EPS of ¥148.31, revenue of ¥619.95B; reaffirms FY outlook
Seeking Alpha · 02/09 11:14
Weekly Report: what happened at ESAIY last week (0202-0206)?
Weekly Report · 02/09 09:38
Biogen projects 2026 revenue drop despite Q4 beat
Seeking Alpha · 02/06 12:02
Weekly Report: what happened at ESAIY last week (0126-0130)?
Weekly Report · 02/02 09:37
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle
Benzinga · 01/28 10:51
Weekly Report: what happened at ESAIY last week (0119-0123)?
Weekly Report · 01/26 09:37
Reported Sunday, Eisai And Biogen Say FDA Accepts LEQEMBI IQLIK sBLA For Weekly Subcutaneous Starting Dose For Early Alzheimer's Disease, Under Priority Review, Action Date May 24, 2026
Benzinga · 01/26 07:01
Weekly Report: what happened at ESAIY last week (0112-0116)?
Weekly Report · 01/19 09:41
Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma
Seeking Alpha · 01/15 15:13
Weekly Report: what happened at ESAIY last week (0105-0109)?
Weekly Report · 01/12 09:39
Weekly Report: what happened at ESAIY last week (1229-0102)?
Weekly Report · 01/05 09:37
Weekly Report: what happened at ESAIY last week (1222-1226)?
Weekly Report · 12/29/2025 09:36
Weekly Report: what happened at ESAIY last week (1215-1219)?
Weekly Report · 12/22/2025 09:36
Weekly Report: what happened at ESAIY last week (1208-1212)?
Weekly Report · 12/15/2025 09:39
Biogen: Alzheimer's Disease Treatment Needs More Real-World Data
Seeking Alpha · 12/15/2025 03:22
Weekly Report: what happened at ESAIY last week (1201-1205)?
Weekly Report · 12/08/2025 09:39
Alzheimer's Clinical Trial Results, Sadly Running True To Form
Seeking Alpha · 12/04/2025 11:30
Weekly Report: what happened at ESAIY last week (1124-1128)?
Weekly Report · 12/01/2025 09:37
Weekly Report: what happened at ESAIY last week (1117-1121)?
Weekly Report · 11/24/2025 09:40
More
Webull provides a variety of real-time ESAIY stock news. You can receive the latest news about Eisai Co Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ESAIY
Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.